This is a list of topics related to HIV/AIDS, a spectrum of conditions caused by human immunodeficiency virus (HIV) infection. Many of the topics listed here were originally taken from the public domain U.S. Department of Health Glossary of HIV/AIDS-Related Terms, 4th Edition. https://web.archive.org/web/20041105064312/http://aidsinfo.nih.gov//ed_resources/glossary/
AACTG â acquired immunity â acquired immunodeficiency syndrome (AIDS) â ACT UP/Golden Gate â active immunity â acupuncture â acute HIV infection â Acute HIV Infection and Early Diseases Research Program (AIEDRP) â ADAP â ADC â adenopathy â adherence â adjuvant â administration â Adult AIDS Clinical Trials Group (AACTG) â adverse drug reaction â aerosolized â AETC â agammaglobulinemia â Agency for Healthcare Research and Quality (AHRQ) â AHRQ â AIDS â AIDS Arms â AIDS dementia complex (ADC) â AIDS Drug Assistance Programs (ADAP) â AIDS education and training centers (AETC) â AIDS orphan â AIDS research advisory committee (ARAC) â AIDS service organization (ASO) â The AIDS Show â AIDS Vaccine 200 â AIDS Vaccine Advocacy Coalition â AIDS wasting syndrome â AIDS-related cancer â AIDS-related complex (ARC) â alkaline phosphatase â alopecia â alpha interferon (INFa) â alternative medicine â alveolar â amebiasis â amino acids â anaphylactic shock â anemia â anergy â angiogenesis â angiomatosis â anorexia â antenatal â antibiotic â antibodies â antibody-dependent cell-mediated cytotoxicity (ADCC) â antibody-mediated immunity â antifungal medication â antigen â antigen presentation â antigen-presenting cell (APC) â antineoplastic â antiprotozoal â antiretroviral drugs â antisense drugs â antitoxins â Antiviral drug â aphasia â aphthous ulcer â apoptosis â approved drugs â ARC â Armenicum â ART â arthralgia â ASO â aspergillosis â assembly and budding â asymptomatic â ataxia â attenuated â autoantibody â autoimmunization â autoinoculation â autologous â avascular necrosis (AVN) â AVN
B-cell lymphoma â B cells â B lymphocytes (B cells) â bactericidal â bacteriostatic â bacterium â baculovirus â baseline â basophil â bDNA test â beta-2 microglobulin (ò2M) â bilirubin â bioavailability â biological response modifiers (BRMs) â biopsy â biotechnology â blinded study â blips â bloodâÂÂbrain barrier â body fat redistribution (BFR) syndrome â body fluids â bone marrow â bone marrow suppression â booster â branched DNA assay â breakthrough infection â Broadway Cares/Equity Fights AIDS â bronchoscopy â budding â buffalo hump â bugchasing and giftgiving â Burkitt's lymphoma
C-T scan (computed tomography scan) â cachexia â Canadian Foundation for AIDS Research â candida â candidiasis â carcinogen â CAT scan â CCR5 â CD4 (T4) or CD4 + cells â CDC National Prevention Information Network (CDC-NPIN) â cell lines â cell-mediated immunity (CMI) â cellular immunity â Centers for Disease Control and Prevention (CDC) â Centers for Medicare and Medicaid Services (CMS) â central nervous system â cerebrum â cerebrospinal fluid (CSF) â cervical cancer â cervical dysplasia â cervical intraepithelial neoplasia (CIN1, CIN2, CIN3) â cervix â chancroid â chemokines â chemoprophylaxis â chemotherapy â Chlamydia â chronic idiopathic demyelinating polyneuropathy (CIPD) â circumoral paresthesia â clade â clinical endpoint â clinical latency â clinical practice guidelines â clinical trial â clinicaltrials.gov â cloning â CMS â CMV â CNS â co-receptors â coccidioidomycosis â codon â cofactors â cognitive impairment â cohort â colitis â combination therapy â community planning â Community Programs for Clinical Research on AIDS (CPCRA) â community-based clinical trial (CBCT) â community-based organization (CBO) â compassionate use â complement â complement cascade â complementary and alternative therapy â complete blood count (CBC) â computed tomography scan (C-T scan) â concomitant drugs â condyloma â condyloma acuminatum â contagious â contraindication â controlled trials â core â core protein â correlates of immunity/correlates of protection â creatinine â cross-resistance â cryotherapy â cryptococcal meningitis â cryptococcosis â Cryptococcus neoformans â cryptosporidiosis â Cryptosporidium â CSF â CTL â cutaneous â CXCR4 â cytokines â cytomegalovirus (CMV) â Cytomegalovirus retinitis â cytopenia â cytotoxic â cytotoxic T lymphocyte (CTL)
DAIDS â data safety and monitoring board (DSMB) â deletion â dementia â demyelination â dendrite â dendritic cells â deoxyribonucleic acid (DNA) â Department of Health and Human Services (DHHS/HHS or DHHS) â desensitization â diabetes mellitus (DM) â diagnosis â diarrhea â diplopia â dissemination â division of acquired immunodeficiency syndrome (DAIDS) â DNA â Domain (biology) â dose-ranging study â dose-response relationship â double-blind study â drug resistance â drug-drug interaction â DSMB â Duffy antigen system â dysplasia â dyspnea
efficacy â empirical â encephalitis â end-stage disease â endemic â endogenous â endoscopy â endotoxin â endpoint â enteric â enteritis â entry inhibitors â Env â envelope â enzyme â enzyme-linked immunosorbent assay (ELISA) â eosinophil â eosinophilic folliculitis â epidemic â epidemiological surveillance â epidemiology â epithelium â epitope â Epstein-Barr virus (EBV) â erythema â erythema multiforme â erythrocytes â etiology â exogenous â exotoxin â expanded access â experimental drug â expression system
fat redistribution â FDA FDC â floaters â follicle â follicular dendritic cells (FDCs) â Food and Drug Administration (United States) functional antibody â fungus â fusin â fusion inhibitor â fusion mechanism â fusion peptide
GAG â gamma globulin â gamma interferon â ganglion â GART â gastrointestinal (GI) â gene â gene therapy â genetic engineering â genital ulcer disease â genital warts â genitourinary tract â genome â genotypic assay â germinal centers â giardiasis â globulins â glycoprotein â gonorrhea â gp120 (gp120) â gp160 (gp160) â gp41 (gp41) â granulocyte â granulocyte macrophage-colony stimulating factor (GM-CSF) â granulocyte-colony stimulating factor (G-CSF) â granulocytopenia
HAART â hairy leukoplakia â half-life â HAM/TSP â Health Care Financing Administration (HCFA) â Health Resources and Services Administration (HRSA) â HELLP syndrome â helper T cells â helper/suppressor ratio (of T cells) â hematocrit â hematotoxic â hemoglobin â hemolysis â hemophilia â hepatic â hepatic steatosis â hepatitis â hepatitis C and HIV coinfection â hepatomegaly â herpes simplex virus 1 (HSV-1) â herpes simplex virus 2 (HSV-2) â herpes varicella zoster virus (VZV) â herpes viruses â highly active antiretroviral therapy (HAART) â histocompatibility testing â histoplasmosis â HIV disease â HIV prevention trials network (HPTN) â HIV set point â HIV vaccine trials network (HVTN) â HIV-1 â HIV-2 â HIV-associated dementia â HIV-related tuberculosis â HLA â Hodgkin's disease â holistic medicine â homology (biology) â hormone â host â host factors â HPTN â HPV â HRSA â HTLV-I â HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) â HTLV-II â human growth hormone (HGH) â human immunodeficiency virus type 1 (HIV-1) â human immunodeficiency virus type 2 (HIV-2) â human leukocyte antigens (HLA) â human papilloma virus (HPV) â human T cell lymphotropic virus type I (HTLV-I) â human T cell lymphotropic virus type II (HTLV-II) â humoral immunity â HVTN â hydroxyurea â hypergammaglobulinemia â hyperglycemia â hyperlipidemia â hyperplasia â hyperthermia â hypogonadism â hypothesis â hypoxia
idiopathic â idiopathic thrombocytopenia purpura â IHS â immune complex â immune deficiency/immunodeficiency â immune response â immune system â immune thrombocytopenic purpura â immunity â immunization â immunocompetent â immunocompromised â immunodeficiency â immunogen â immunogenicity â immunoglobulin (Ig) â immunoglobulin A (IgA) â immunoglobulin D (IGD) â immunoglobulin E (IGE) â immunoglobulin G (IGG) â immunoglobulin M (IGM) â immunomodulator â immunostimulant â immunosuppression â immunotherapy â immunotoxin â in vitro â in vivo â incidence â Incubation period â IND â Indian Health Service (IHS) â infection â infectious â informed consent â infusion â inoculation â institutional review board (IRB) â integrase â integrase inhibitors â Interaction â interferon â interleukin-1 (IL-1) â interleukin-2 (IL-2) â interleukin-4 (IL-4) â interleukin-12 (IL-12) â interleukins â International Center for Research on Women â intramuscular (IM) â intravenous â intravenous immunoglobulin (IVIG) â intravitreal â Investigational New Drug (IND) â IRB â ITP â IVIG
Kaposi's sarcoma (KS) â Karnofsky score â killer T cells â KSHV â Kupffer cells
Langerhans cells â LAS â lentivirus â lesion â leukocytes â leukocytosis â leukopenia â leukoplakia â LFT â LIP â lipid â lipodystrophy â liposomes â live vector vaccine â liver function test (LFT) â long terminal repeat sequence (LTR) â long-term nonprogressors â LTR â lumbar â lumbar puncture â lymph â lymph nodes â lymphadenopathy syndrome (LAS) â lymphatic vessels â lymphocyte â lymphoid interstitial pneumonitis (LIP) â lymphoid organs â lymphoid tissue â lymphokine-activated killer cells (LAK) â lymphokines â lymphoma â lymphopenia â lymphoproliferative response â lysis
MAC â macrophage â macrophage-tropic virus â magnetic resonance imaging (MRI) â MAI â maintenance therapy â major histocompatibility complex (MHC) â malabsorption syndrome â malaise â malignant â mast cell â MedlinePlus â mega-HAART â memory T cells â meninges â meningitis â messenger RNA â metabolism â metastasis â MHC â microbes â microbicide â Microsporidiosis â mitochondria â mitochondrial toxicity â molecule â molluscum contagiosum â monocyte â mononeuritis multiplex (MM) â monovalent vaccine â morbidity â MRI â mucocutaneous â mucosa â mucosal immunity â mucous membrane â Multicenter AIDS Cohort Study â multi-drug rescue therapy â multiple drug-resistant tuberculosis (MDR-TB) â mutation â myalgia â mycobacterium â mycobacterium avium complex (MAC) â mycosis â myelin â myelopathy â myelosuppression â myelotoxic â myocardial â myopathy
NAT â National Cancer Institute (NCI) â National Institute of Allergy and Infectious Diseases (NIAID) â National Institute of Child Health and Human Development (NICHD) â National Institutes of Health (NIH) â National Library of Medicine (NLM) â National Prevention Information Network (NPIN) â natural history study â natural killer cells (NK cells) â NCI â New Drug Application â nebulized â Nef â neoplasm â nephrotoxic â neuralgia â neurological complications of AIDS â neuropathy â neutralization â neutralizing antibody â neutralizing domain â neutropenia â neutrophil â New Drug Application (NDA) â New York Cares â NIAID â NICHD â night sweat â NIH â NK cell â NLM â NNRTI â non-Hodgkin's lymphoma (NHL) â non-nucleoside reverse transcriptase inhibitors (NNRTI) â non-steroidal anti-inflammatory drugs (NSAID) â NRTI â nucleic acid â nucleic acid test â nucleocapsid â nucleoli â nucleoside â nucleoside analog â nucleoside reverse transcriptase inhibitors (NRTI) â nucleotide â nucleotide analogs â nucleus â null cell
ocular â off-label use â oncology â open-label trial â opportunistic infections â oral hairy leukoplakia (OHL) â organelle â oropharyngeal â orphan drugs â osteonecrosis â osteopenia
P24 â package insert â palliative â palliative care â pancreas â pancreatitis â pancytopenia â pandemic â pap smear â papilloma â parallel track â parasite â parenteral â paresthesia â passive immunity â passive immunotherapy â pathogen â pathogenesis â PBMC â PCP â PCR â Pediatric AIDS Clinical Trial Group (PACTG) â pelvic inflammatory disease â peptide â perianal â perinatal â perinatal transmission â peripheral neuritis â peripheral neuropathy â persistent generalized lymphadenopathy â PGL â phagocyte â phagocytosis â pharmacokinetics â phase I trials â phase II trials â phase III trials â phase IV trials â photosensitivity â PHS â pituitary gland â placebo â placebo controlled study â placebo effect â plasma â plasma cells â platelets â PML â Pneumocystis jiroveci pneumonia (formerly Pneumocystis carinii or PCP) â POL â polymerase â polymerase chain reaction (PCR) â polyneuritis â polypeptide â polyvalent vaccine â post-exposure prophylaxis (PEP) â PPD test â pre-conception counseling â preclinical â precursor cells â prevalence â primary HIV infection â primary isolate â primaquine â proctitis â prodrome â prodrug â progressive multifocal leukoencephalopathy (PML) â prophylactic drug â prophylaxis â protease â protease inhibitors â protease-sparing regimen â proteins â protocol â protozoa â provirus â pruritus â pseudo-Cushing's syndrome â pseudovirion â PUBMED â pulmonary â purified protein derivative (PPD)
radiology â randomized trial â rebound â receptor (immunology) â recombinant â recombinant DNA â recombinant DNA technology â regulatory genes â regulatory T cells â remission â renal â rescue therapy â resistance â retina â retinal detachment â retinitis â retrovirus â REV â reverse transcriptase â ribonucleic acid (RNA) â ribosome â RNA â route of administration â RT-PCR â RTI â Ryan White C.A.R.E. act
safe sex â safer sex â salmonella â salvage therapy â SAMHSA â sarcoma â seborrheic dermatitis â secondary prophylaxis â sepsis â seroconversion â serologic test â seroprevalence â serosorting â serostatus â serum â serum glutamic oxaloacetic transaminase (SGOT) â serum glutamic pyruvate transaminase (SGPT) â sexually transmitted disease (STD) â shingles â SHIV â side effects â simian immunodeficiency virus (SIV) â sinusitis â social integration SIT â SIV â Special Projects of National Significance (SPNS) â spinal tap â spleen â splenomegaly â sputum analysis â standard of care â staphylococcus â STD â stem cells (FDCs) â steroid â StevensâÂÂJohnson syndrome â STI â stomatitis â strain â stratification â structured intermittent therapy (SIT) â structured treatment interruption (STI) â study endpoint â subarachnoid space â subclinical infection â subcutaneous (SQ) â Substance Abuse and Mental Health Services Administration (SAMHSA) â subunit HIV vaccine â sulfa drug â sulfonamides â superantigen â suppressor T cell â surrogate marker â surveillance â susceptible â symptoms â syncytium â syndrome â synergy â synergistic â synthesis â syphilis â systemic
T cells (T lymphocytes) â T lymphocyte proliferation assay â T lymphocytes â T suppressor cells â T4 cells (T-helper cells) â T8 cells â Tanner staging â TAT â TB â template â TeachAids â teratogenicity â testosterone â therapeutic HIV vaccine â thrombocytopenia â thrush â thymosin â thymus â tissue â titer â toxicity â toxoplasmic encephalitis â toxoplasmosis â transaminase â transcription â transfusion â translation â transmission â transplacental â treatment IND â triglycerides â tuberculin skin test (TST) â tuberculosis (TB) â tumor necrosis factor (TNF)
V3 loop â vaccination â vaccine â vaccinia â vaginal candidiasis â valley fever â variable region â varicella zoster virus (VZV) â vector â vertical transmission â viral burden â viral core â viral culture â viral envelope â viral load â viremia â viricide â virion â virology â virus â visceral
wasting syndrome â Western blot â white blood cells â wild-type virus â window period â Women's Interagency HIV Study (WIHS) â World AIDS Day â World AIDS Vaccine Day
yeast infection â Youth Against AIDS